Mail

ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

69.37

+4.30 (+6.61%)

At close: 4:00PM EST

69.37 0.00 (0.00%)
After hours: 4:32PM EST

Stock chart is not supported by your current browser

Previous Close	65.07
Open	64.90
Bid	62.10 x 900
Ask	75.00 x 1200
Day's Range	63.57 - 70.53
52 Week Range	63.57 - 153.99
Volume	846,899
Avg. Volume	941,253

Market Cap	7.008B
Beta (3Y Monthly)	3.29
PE Ratio (TTM)	N/A
EPS (TTM)	-5.87
Earnings Date	Feb 6, 2019 - Feb 11, 2019
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	132.41

Trade prices are not sourced from all markets

All

News

Press Releases

PR Newswire5 hours ago
Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important November 26 Deadline in Class Action - ALNY
NEW YORK , Nov. 15, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through ...
ACCESSWIRE6 hours ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. to Contact the Firm
NEW YORK, NY / ACCESSWIRE / November 15, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Alnylam stock or options between February 15, 2018 and September 12, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/ALNY. You can also contact us by calling Richard Gonnello toll free at877-247-4292 or at 212-983-9330 or by sending an e-mail torgonnello@faruqilaw.com.
Motley Fool6 hours ago
Alnylam Pharmaceuticals Launches Onpattro
Unfortunately, predicting the steepness of the launch is going to be tough.
ACCESSWIRE13 hours ago
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) & Lead Plaintiff Deadline - November 26, 2018
NEW YORK, NY / ACCESSWIRE / November 15, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. ("Alnylam" ...
ACCESSWIREyesterday
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ALNY
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (ALNY) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and index under 18-cv-08845, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Alnylam securities between February 22, 2017 and July 19, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
ACCESSWIREyesterday
ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. – ALNY
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ...
ACCESSWIREyesterday
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 14, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2018 and September 12, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 26, 2018.
GlobeNewswire2 days ago
CLASS ACTION UPDATE for MCHP, COCP and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Nov. 13, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
ACCESSWIRE2 days ago
DEADLINE RAPIDLY APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 13, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2018 and September 12, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 26, 2018.
Thomson Reuters StreetEvents2 days ago
Edited Transcript of ALNY earnings conference call or presentation 7-Nov-18 1:30pm GMT
Q3 2018 Alnylam Pharmaceuticals Inc Earnings Call
Market Realist3 days ago
Jazz Pharmaceuticals: Analysts’ View in November
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9. On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which is ~19% below its 52-week high of $184.00 on June 20.
Markit3 days ago
See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
GlobeNewswire3 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MCHP, ALNY, CHGG, FIT and SONS
NEW YORK, Nov. 12, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
ACCESSWIRE3 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (ALNY) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and index under 18-cv-08845, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Alnylam securities between February 22, 2017 and July 19, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Motley Fool3 days ago
Ionis Pharmaceuticals Collects Royalties -- and Spends It All
With $2 billion in the bank, the biotech can afford to invest in the future.
ACCESSWIRE3 days ago
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 12, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2018 and September 12, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 26, 2018.
GlobeNewswire4 days ago
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder For Alnylam Pharmaceuticals, Inc. Investors
Important Deadline Reminder: Investors who purchased Alnylam securities during the Class Period may, no later than November 26, 2018, seek to be appointed as a lead plaintiff representative of the class.
GlobeNewswire4 days ago
INVESTOR REMINDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. (“Alnylam” or “the Company”) (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
Markit4 days ago
See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
GlobeNewswire5 days ago
SHAREHOLDER ALERT: ALNY ACHC JT TRVN HON DY AQUA SONS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Nov. 11, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
ACCESSWIRE6 days ago
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 9, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2018 and September 12, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 26, 2018.
GlobeNewswire6 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ALNY
Pomerantz LLP announces that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (ALNY) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and index under 18-cv-08845, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Alnylam securities between February 22, 2017 and July 19, 2018, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Markit7 days ago
See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
Business Wire7 days ago
Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the Company presented updated results from the ongoing Phase 1/2 open-label extension (OLE) study of givosiran, an investigational RNAi therapeutic, targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP). “We are encouraged by the sustained clinical activity and safety profile of givosiran in the ongoing Phase 1/2 OLE study, now with up to over two years of dosing.
ACCESSWIRE7 days ago
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 8, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2018 and September 12, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 26, 2018.